KEYNOTE-177-5YR

NCT02563002 📎

Regimen

Experimental
Pembrolizumab 200 mg Q3W (up to 35 cycles)
Control
Investigator's choice chemotherapy (FOLFOX or FOLFIRI ± bevacizumab or cetuximab)

Population

MSI-H/dMMR metastatic CRC, 1L, centrally confirmed; 5-year long-term follow-up of KEYNOTE-177 (long-term follow-up).

Key finding

At median follow-up 73.3 months: median OS 77.5 vs 36.7 months (HR 0.73, 95% CI 0.53–0.99); 5-year OS 54.8% vs 44.2%; median PFS 16.5 vs 8.2 months (HR 0.60, 95% CI 0.45–0.79); median duration of response 75.4 months (pembro) vs 10.6 months (chemo); grade ≥3 AEs: 22% vs 67%; effective crossover to PD-(L)1 inhibitor 62%.

Source: PMID 39631622

Timeline

    Guideline citations

    • NCCN Colon (p.59)
    • NCCN Rectal (p.76)